Canine α-synuclein antibody and antigen (recombinant protein)

 Download 

Product information

Catalog No.	Description	US $ Price (per mg)
GMP-CAN-a-synuclein-Ag01	Recombinant Canine α-synuclein protein	3090
GMP-CAN-a-synuclein-Ab01	Anti-Canine α-synuclein mouse monoclonal antibody (mAb)	1953
GMP-CAN-a-synuclein-Ab02	Anti-Canine α-synuclein mouse monoclonal antibody (mAb)	1953
GMP-CAN-a-synuclein-Ab03	Anti-Canine α-synuclein human monoclonal antibody (mAb)	1953
GMP-CAN-a-synuclein-Ab04	Anti-Canine α-synuclein human monoclonal antibody (mAb)	1953

Size： 1mg | 10mg | 100mg

Product Description

Cat No. of Products	GMP-CAN-a-synuclein-Ag01
Product Name	Recombinant Canine α-synuclein protein
Target/Biomarker	Canine Alpha-synuclein (α-synuclein)
Expression platform	E.coli
Isotypes	Recombinant Antigen
Bioactivity validation	Anti-Canine Alpha-synuclein antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in α-synuclein level test of animal Dog/Canine with Alzheimer Disease(AD).
Tag	His
Products description	Recombinant Canine α-synuclein protein was expressed in E.coli - based prokaryotic cell expression system and is expressed with 6 HIS tag at the C-terminus.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays
Formulation & Reconstitution	Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O.
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Cat No. of Products	GMP-CAN-a-synuclein-Ab01, GMP-CAN-a-synuclein-Ab02
Product Name	Anti-Canine α-synuclein mouse monoclonal antibody (mAb)
Target/Biomarker	Canine Alpha-synuclein (α-synuclein)
Expression platform	CHO
Isotypes	Mouse IgG
Bioactivity validation	Recombinant Canine Alpha-synuclein antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-α-synuclein antibodies in α-synuclein level test of animal Dog/Canine with Alzheimer Disease(AD).
Tag	mFc
Products description	Anti-Canine α-synuclein mouse monoclonal antibody (mAb) is a monoclonal antibody produced by CHO technology. The antibody is ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-α-synuclein antibodies.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays
Formulation & Reconstitution	Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O.
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Cat No. of Products	GMP-CAN-a-synuclein-Ab03, GMP-CAN-a-synuclein-Ab04
Product Name	Anti-Canine α-synuclein human monoclonal antibody (mAb)
Target/Biomarker	Canine Alpha-synuclein (α-synuclein)
Expression platform	CHO
Isotypes	Human IgG1
Bioactivity validation	Recombinant Canine Alpha-synuclein antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-α-synuclein antibodies in α-synuclein level test of animal Dog/Canine with Alzheimer Disease(AD).
Tag	hFc
Products description	Anti-Canine α-synuclein human monoclonal antibody (mAb) is a monoclonal antibody produced by CHO technology. The antibody is ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-α-synuclein antibodies.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays
Formulation & Reconstitution	Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O.
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference

Validation Data

Click to get more Data / Case study about the product.

Target/Biomarker information

Canine α-synuclein, an evolutionary kin of its human counterpart, emerges as a fascinating player in the intricate symphony of the canine nervous system. At its core, this protein is an intrinsically disordered marvel, defying traditional structural classifications. Structurally, it bears resemblance to a "Janus-faced" molecule, with its N-terminal portion embracing amphipathic tendencies, a hydrophobic central domain, and an acidic, largely negatively charged C-terminal tail. This unique structure hints at its multifunctionality within the neuronal milieu. Canine α-synuclein's primary residence is in the central nervous system, where it assumes an array of roles. Among its most noteworthy functions is its involvement in the regulation of synaptic vesicle dynamics. It dynamically associates with synaptic vesicles, modulating their trafficking and neurotransmitter release. This role positions Canine α-synuclein as a key player in the finely tuned orchestra of synaptic transmission. Beyond the mechanics of neurotransmission, Canine α-synuclein partakes in the orchestration of synaptic plasticity, a fundamental process underpinning learning and memory. Its presence influences synaptic strength and the molecular cascades that contribute to adaptive changes in neural circuits. This dynamic role positions Canine α-synuclein as a molecular conductor of cognitive processes in dogs. Yet, the intrigue surrounding Canine α-synuclein deepens as we explore its darker side—the propensity to aggregate. Much like its human counterpart, Canine α-synuclein can undergo conformational changes that lead to the formation of insoluble protein aggregates, famously known as Lewy bodies. These aggregates are central to the pathogenesis of neurodegenerative disorders, particularly in elderly dogs. The exact triggers and mechanisms governing this transition into aggregation-prone states are areas of intense research. Understanding these processes is instrumental in uncovering potential therapeutic targets to mitigate the devastating effects of neurodegenerative diseases in dogs.

About GDU